Biotech · Public company · Boston, MA, US
Transcode Therapeutics, Inc.
Ticker RNAZ · SEC CIK 0001829635
Track this companyFree. Adds Transcode Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials32 recruiting or active
Pipeline programs2From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline2
- TTX-MC138Phase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- TTX-MC138-NODAGA-Cu64Phase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials3
- Study of TTX-MC138 in Subjects With Advanced Solid TumorsPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Sep 5, 2024ClinicalTrials.gov NCT06260774 · fetched Nov 12, 2026
- A Microdose Study of TTX-MC138-NODAGA-Cu64 in Subjects With Advanced Solid TumorsEARLY_PHASE1 · COMPLETED · started Apr 4, 2023ClinicalTrials.gov NCT05908773 · fetched Nov 12, 2026
- PRE-ISPY Phase I/II Oncology Platform ProgramPHASE1_PHASE2 · RECRUITING · started Feb 15, 2023ClinicalTrials.gov NCT05868226 · fetched Nov 12, 2026
SEC filings12
- 8-K · FORM 8-KSEC EDGAR · filed Oct 28, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Oct 1, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Sep 28, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Sep 11, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 14, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Aug 3, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jul 20, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jul 17, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jul 2, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jun 18, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jun 3, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jun 1, 2026 · fetched Nov 12, 2026
NIH awards2
- Phase I Clinical Testing of a First-in-Class Therapy against Metastatic CancerFiscal year 2025 · $988.8KNIH RePORTER 5R44CA295173-02 · fetched Nov 12, 2026
- Phase I Clinical Testing of a First-in-Class Therapy against Metastatic CancerFiscal year 2024 · $1MNIH RePORTER 1R44CA295173-01 · fetched Nov 12, 2026